Courses

← vista completa

Published on December 1, 2002 | http://doi.org/10.5867/medwave.2002.11.3504

New therapies in lung cancer IV

Nuevas terapias en el cáncer de pulmón IV

Elsa Cabrera Acosta

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Elsa Cabrera Acosta

Hospital Clínico Universidad de Chile, Santiago, Chile

Figures

Article has no figures.

Forum

No messages

History

Citation Cabrera Acosta E. New therapies in lung cancer IV. Medwave 2002;2(11):e3504 doi: 10.5867/medwave.2002.11.3504

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/12/2002

Index

Metrics

Not available at the moment.

Notes

References

  1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27. | CrossRef
  2. Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg. 1999 Dec;118(6):1136-52. | CrossRef
  3. Chaudhry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC, Bartholomew R,et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res. 1999 Nov;5(11):3385-93. | PubMed
  4. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor related peptides and their recoeptors in human malignancies. Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232. | CrossRef
  5. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti epidermal gowth factor receptor monoclonal antibody 225 up regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU 145. Cancer Res. 1996 Aug 15;56(16):3666-9. | PubMed
  6. Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB- 2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 1994 Jul 15;13(14):3302-11. | PubMed
  7. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 1994 Jun 15;54(12):3260-6. | PubMed
  8. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T,et al. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res. 1996 Jan 1;56(1):206-9. | PubMed
  9. Bunn PA Jr, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR,et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 2001 Oct;7(10):3239-50. | PubMed
  10. Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 2000 Jul 15;60(14):3782-9. | PubMed
  11. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G,et al. The microtubule-affecting drug paclitaxel has anti-angiogenic activity. Clin Cancer Res. 1996 Nov;2(11):1843-9. | PubMed
  12. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD,et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 2001 Jan 15;61(2):739-48. | PubMed
  13. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997 Nov 1;57(21):4838-48. | PubMed
  14. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood. 2000 Aug 1;96(3):925-32. | PubMed
  15. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000 Aug;6(8):3319-26. | PubMed
  16. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM,et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol. 2001 Apr 15;19(8):2319-33. | PubMed
  17. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol. 2001 Mar 1;19(5):1485-92. | PubMed
  18. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer. 1995 Aug;72(2):461-8. | CrossRef | PubMed
  19. Yuen A, Halsey J, Fisher G, et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol. 2001;20:309a
  20. Adjei AA. Blocking oncogenic ras signaling for cancer therapy J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74. | CrossRef | PubMed
  21. Dang T, Johnson DH, Kelly K, et al. Multicenter phase II trial of an antisense inhibitor of H-ras (ISIS-2503) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol.2001;10:332a.
  22. Adjei AA. Farnesyltransferase inhibitors, in Giaccone G, Schilsky R, Sondel P (eds): Cancer Chemotherapy and Biologic Response Modifiers: Annual 19. Amsterdam, the Netherlands, Elsevier, 2001, p 149-164
  23. Wojtowicz ME, Hamilton MJ, Bernstein S, et al. Clinical trial of mutant ras peptide vaccination along with IL-2 or GM-CSF. Proc Am Soc Clin Oncol. 2000;19:463a.
  24. Stevenson JP, Yao KS, Gallagher M, et al: Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol. 1999; 17: p.2227-2236. | PubMed
  25. Sebolt-Leopold JS. CI-1040: A novel small molecule MEK inhibitor with broad spectrum antitumor activity. Clin Cancer Res. 2001;7:3819
  26. Blume-Jensen P, Janknecht R, Hunter T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of bad on Ser136. Curr Biol.1998;8:779-782. | CrossRef
  27. Lotan R. Retinoid and apoptosis. Implication for cancer chemoprevention and therapy. J Natl Cancer Inst. 1995; 87:1655-1657 | CrossRef
  28. Camerini T, Mariani L, De Palo G, et al. Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol. 2001; 19:1664-1670. | PubMed
  29. Khuri FR, Rigas JR, Figlin RA, et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol.2001; 15:p.2626-2637.
  30. Braun BC, Glickman M, Kraft R, et al. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nature Cell Biol. 1999; 1:221-226. | CrossRef | PubMed
  31. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 1999; 59:p.2615-2622. | PubMed
  32. Erlichman C, Adjei AA, Thomas JP, et al: A Phase I trial of the proteasome inhibitor PS-341 in patients with advanced cancer. Proc Am Soc Clin Oncol 20: 85a, 2001 (abstr 337) 33.Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996; 56:p.2973-2978. | PubMed
  33. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998; 16:p.2986-2999. | PubMed
  34. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998; 16:p.2986-2999. | PubMed
  35. Shapiro G, Supko JG, Patterson A, et al. A phase II trial of cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res. 2001; 7: 1590-1599. | PubMed
  36. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated ß-catenin. Cancer Res. 2000; 60:p.3338-3342 | PubMed
  37. Soriano AF, Helfrich B, Chan DC, et al. Synergistic effects of new chemopreventive agents and the conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999; 59:p.6178-6184. | PubMed
  38. Hida T, Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res.1998; 58:3761-3764 | PubMed
  39. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992; 52:4828-4831. | PubMed
  40. Hamada M, Fujiwara T, Hizuta A, et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol. 1996; 122:360-365 | CrossRef | PubMed
  41. Roth JA, Nhuyen D, Lawrence DD, et al: Retrovirus-mediated wildtype p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996; 2:985-991. | CrossRef | PubMed
  42. Nemunaitis J, Swisher SG, Timmons T, et al: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J Clin Oncol. 2000; 18:609-622. | PubMed
  43. Schuler M, Hermann R, De Greve JLP, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study. J Clin Oncol. 2001; 19:1750-1758. | PubMed
  44. You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res. 2000; 60:1009-1013. | PubMed
  45. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999; 11:68-75. | CrossRef | PubMed
  46. Rudin C, Otterson GA, George CM, et al. A phase I/II trial of genasense and paclitaxel in chemorefractory small cell lung cancer. Proc Am Soc Clin Oncol. 2001; 20:322a.
  47. Keshet E, Ben-Sasson SA. Anticancer drug targets: Approaching angiogenesis. J Clin Invest. 1999; 104:1497-1501. | CrossRef | PubMed
  48. DeVore RF, Fehrenbacher L, Herbst RS, et al. A randomized phase II trial comparing rhumAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol. 2000;19:485a Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000; 105:R15-R24. | CrossRef | PubMed
  49. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000 Apr;105(8):R15-24. | CrossRef | PubMed
  50. Mendel DB, Schreck RE, West DC, et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res. 2000; 6:4848-4858. | PubMed
  51. Workman P, Brunton VG, Robins DJ. Tyrosine kinase inhibitors. Semin Cancer Biol. 1992; 3:369-381. | PubMed
  52. Basser R, Hurwitz H, Barge A, et al. Phase I pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors. Proc Am Soc Clin Oncol. 2001; 20:100a.
  53. Pavco PA, Bouhana KS, Gallegos AM, et al: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res. 2000; 6:2094-2103. | PubMed
  54. Akhter S, Nath SK, Tse CM, et al. Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na+/H+ exchanger isoform NHE3. Am J Physiol. 1999; 276:C136-144. | PubMed
  55. O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997 Jan 24;88(2):277-85. | CrossRef
  56. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M,et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999 Apr 23;274(17):11721-6. | CrossRef | PubMed
  57. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy J Natl Cancer Inst. 2001 Feb 7;93(3):178-93. | CrossRef
  58. Munoz-Mateu M, de’Grafenried L, Eckhardt SG, et al: Pharmacodynamic studies of Col-3, a novel matrix metalloproteinase inhibitor, in patients with advanced cancer. Proc Am Soc Clin Oncol., 2001; 20:76a Dupont E, Falardeau P, Mousa SA, Dimitriadou V, Pepin MC, Wang T, et al. Antiangiogenic and antimetastatic properties of neovastat (Æ-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis. 2002;19(2):145-53. | CrossRef | PubMed
  59. Dupont E, Falardeau P, Mousa SA, Dimitriadou V, Pepin MC, Wang T,et al. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis. 2002;19(2):145-53. | CrossRef | PubMed
  60. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin vß3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994 Dec 30;79(7):1157-64. | CrossRef
  61. Eskens F, Dumez H, Verweij J, et al. Cilengitide (EMD 121974) inhibits angiogenesis by blocking vß3 and vß5 integrins; mature results of a phase I and pharmacological study. Clin Cancer Res. 2000; 6:4524s.
  62. Vangsted AJ, Clausen H, Kjeldsen TB, et al: Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1) antigen in serum. Cancer Res. 1991; 51:p.2879-2884. | PubMed
  63. Grant SC, Kris MG, Houghton AN, et al: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette Guerin. Clin Cancer Res. 1999; 9:1319-1323.
  64. Thompson J, Zimmermann W: The carcinoembryonic antigen gene family: Structure, expression, and evolution. Tumor Biol., 1988; 9:63-83 | CrossRef | PubMed
  65. Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol. 1999 Oct;29(10):3329-37. | CrossRef
  66. Rosenberg SA: The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J Sci Am. 1995 Jul-Aug;1(2):90-100. | PubMed
  67. Bowne WB, Wolchok JD, Hawkins WG, Srinivasan R, Gregor P, Blachere NE, et al. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell Mol Ther. 1999 Dec;5(4):217-25. | PubMed